Cryoport Financial Report from Smith On Stocks

Monday, March 8, 2021 · 8:01 am

Friday, February 19, 2021 · 9:12 am

Tuesday, January 26, 2021 · 9:06 am

Thursday, January 21, 2021 · 6:08 pm

Wednesday, November 18, 2020 · 9:21 am

Wednesday, November 18, 2020 · 9:02 am

Monday, November 16, 2020 · 2:03 pm

Monday, November 9, 2020 · 11:49 am

Monday, August 31, 2020 · 3:21 pm

Thursday, August 20, 2020 · 9:31 am

Friday, May 15, 2020 · 12:28 pm

Monday, January 13, 2020 · 3:20 pm

Thursday, December 12, 2019 · 10:32 am

Wednesday, November 27, 2019 · 8:28 am

Friday, October 18, 2019 · 10:55 am

Thursday, August 8, 2019 · 8:46 pm

Thursday, June 20, 2019 · 3:20 pm

Monday, May 20, 2019 · 11:31 am

Friday, March 8, 2019 · 12:53 pm

Tuesday, January 8, 2019 · 9:55 am

Monday, December 17, 2018 · 10:35 am

Friday, November 16, 2018 · 3:53 pm

Thursday, September 27, 2018 · 9:55 am

Tuesday, August 14, 2018 · 11:13 am

Wednesday, May 16, 2018 · 11:38 am

Thursday, March 29, 2018 · 12:59 pm

Wednesday, March 7, 2018 · 10:43 am

Monday, November 6, 2017 · 9:26 am

Thursday, August 10, 2017 · 11:48 am

Wednesday, July 26, 2017 · 8:26 am

Wednesday, July 19, 2017 · 9:40 am

Tuesday, July 11, 2017 · 5:40 pm

Thursday, May 11, 2017 · 4:00 pm

Thursday, April 27, 2017 · 8:39 am

Wednesday, April 12, 2017 · 11:07 am

There are 35 reports on file.

Reports on Cryoport

Reports on Cryoport

Recent Reports

Cryoport: Update on My Investment Thinking (CYRX, Buy, $49.35)

Cryoport (CYRX, Buy, $66.00) and bluebird bio: Investment Significance of bluebird�s Decision to Temporarily Suspend Sickle Cell Disease Trials of LentiGlobin and Marketing of Zynteglo in Europe

Cryoport (CYRX, Buy, $72.30) Kymriah Sales are Strong and Equity Offering Was Well Received

Cryoport: Comments on Just Completed Equity Offering and Surprising 15% Surge in Stock Price (CYRX, Buy, $73.75)

Cryoport; How Airlines Might Need Cryoport Dewars for Shipping of COVID-19 Vaccines (CYRX, Buy, $46.43)

Cryoport: Potential Commercial Benefits from COVID-19 Vaccines (CYRX, Buy, $46.43)

Cryoport: Comments on the Sharp Recent Price Swings (CRYX, $51.86, Buy)

Cryoport: We Are Just in the First Inning (CYRX, Buy, $50.27)

Cryoport: My Take on the Recent Acquisitions and Strong Move in the Stock (CYRX, Buy, $55.50)

Cryoport Has Staggering Growth Potential but Is the Stock Overpriced (CYRX, $33.51, Buy)

Cryoport (CYRX, $23.71, Buy) : Great Potential for Substantial increases in Commercial Sales in the 2020 to 2024 Timeframe

Cryoport: Pre-Announcement of 4Q Sales Negatively Impacted Stock; I Remain Bullish on the Stock (CYRX, Buy, $18.07)

Cryoport: Exciting Clinical Data on CAR-T Drugs Points to Dramatic Growth (CYRX, Buy, $14.59)

Cryoport: A Model Projecting How Commercially Approved Products Supported by Cryoport Will Drive Growth Through 2024 (CYRX, Buy, $15.12)

Cryoport: Stock Has Been Attacked by Short Sellers (CYRX, $14.57, Buy)

Cryoport: Quick Take on 2Q Results (CYRX, $20.18, Buy)

Cryoport: I View the Just Completed Equity Offering as a Major Positive (CYRX, Buy, $18.00)

Cryoport: Details of My Model for Sales for 2018 to 2024 (CYRX, Buy, $16.88)

Cryoport: Great Buying Opportunity (CYRX. Buy, $10.44)

Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport (CYRX, Buy, $9.05)

Cryoport Raises a $25 Million Warchest for Acquisitions (CYRX, $9.45, Buy)

Cryoport: Detailed Update and Updated Projections Based on 3Q Results (CYRX, Buy, $10.35)

Regenerative Medicine: Thoughts on How to Invest in This Dynamic New Technology

Cryoport: Reiterating My Buy Recommendation (CYRX, Buy, $14.20)

Cryoport: Updated Sales and Earnings Model (CYRX, Buy, $9.69)

Cryoport: Gilead Update on Yescarta Strongly Supports My View That Cryoport has Explosive Sales Growth; An Important Upward Inflection is Approaching (CYRX, $8.75, Buy)

Cryoport: Continuing to Pound the Table on this Unique Growth Story (CYRX, Buy $9.17)

Cryoport: This Unique Company is Poised for Explosive Sales Growth; Price Weakness is a Buying Opportunity (CYRX, Buy, $6.68)

Cryoport: As Its Clients Transition from Clinical Development to Commercial, Growth Could Be Explosive (CYRX, $6.89, Buy)

Cryoport: Upping 2020 Price Target from $14.50 to $20.00 (CYRX, Buy, $6.89)

My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)

Cryoport: Thoughts About FDA AdCom Meeting on Novartis�s CAR-T Drug Tisagenlecleucel (CYRX, Buy, $4.86)

Cryoport: Observations on 1Q, 2017 Results (CYRX, Buy, $3.05)

Thoughts on the Probable Launches of the First CAR-T Drugs; Cryoport is a Novel Way to Invest In This: Cryoport (CYRX, Buy, $2.36) and Kite (KITE, Neutral, $83.37)

Cryoport: Initiating Coverage of this Highly Unique Health Care Company with a Buy (CYRX, Buy, $2.25)